Policygenius | December 30, 2022
Over the last six years, psychedelic drugs have gained increasing acceptance in the medical and legal realms as legitimate treatments for mental health conditions. Nathan Sackett, MD, MS, says researchers are finding growing evidence that psychedelics can help treat conditions like depression, anxiety, and substance abuse.
Right as Rain | July 5, 2022
Ketamine can help alleviate symptoms of depression and lessen suicidal thoughts quickly, but ketamine treatment is not for everyone, says Nathan Sackett, MD, MS.
The Seattle Times | April 23, 2022
Scientists, doctors, advocacy workers, and other community members gathered to discuss the next frontier of treating substance-use disorders and addiction: psychedelics. The meeting was convened by the Center for Novel Therapeutics in Addiction Psychiatry led by Nathan Sackett, MD.
Seattle Met | February 22, 2022
Seattle became the largest U.S. city to decriminalize psychedelic drugs. To be clear, decriminalization isn’t legalization, and the gateway legislation doesn’t apply to LSD, MDMA or ketamine. But it may signal a more permissive psychedelic future. Nathan Sackett, MD, RS, RN, is quoted.
KXLY.com | February 2, 2022
Washington lawmakers will consider legalizing the use of psilocybin to treat various illnesses like PTSD and depression. Nathan Sackett, MD, MS, told the committee: "Evidence currently suggests that psilocybin, when given in a controlled environment under the care of a provider, may significantly reduce symptoms of depression, anxiety, trauma and a range of substance abuse disorders."
Right as Rain | November 15, 2021
Microdosing psilocybin has become trendy among people hoping to alleviate anxiety or increase creativity. Nathan Sackett, MD, MS, talks about its promise as a therapeutic agent and his plans to build a novel therapeutics research program that will explore the pairing of compounds like psilocybin and ketamine with behavioral interventions to treat addictions.
Department news | June 30, 2021
Nathan Sackett, MD, MS, is the first recipient of the Department of Psychiatry and Behavioral Sciences new Clinician Scientist Transition (CST) Award. Funded by philanthropic and departmental support, the award provides funds to advance the career of clinician scientists who are committed to starting careers in clinical or translational research. Finding time to pursue research interests is difficult while fully engaged in clinical and teaching responsibilities, and the CST Award supports this career trajectory by protecting a clinician scientist’s time to do so.